- [Interview] Jeong Hotcherl, CEO of Bion 스피드 바카라 사이트
- Oral delivery of GLP-1 drugs with ionic 스피드 바카라 사이트-based platform technologies
- Overcoming formulation barriers: Platform expands application to other peptides, RNA, and vaccines
- Chosen for a membership company of K-BioLab Hub
[by Kang, In Hyo] “Bion Liquid is developing a next-generation drug delivery platform utilizing ionic liquid technology. This platform enables the conversion of peptide therapeutics, including those in the glucagon-like peptide 1 (GLP-1) series, globally sought for the treatment of diabetes and obesity, into oral formulations, offering a promising alternative to conventional injectable forms.”
In an interview with THE BIO on May 16, Jeong Hotcherl, CEO and Co-founder of biotech startup Bion 스피드 바카라 사이트, which is developing a next-generation drug delivery platform based on ionic 스피드 바카라 사이트s, highlighted the company’s core strengths. “Our mission is to address challenges in the biotech industry through the application of ionic 스피드 바카라 사이트 technology,” Jeong stated.
Established in April 2023, Bion 스피드 바카라 사이트 marks its second anniversary last month. The company, a biotech startup specializing in the integration of chemistry, biology, and pharmaceutical sciences, was co-founded by Dr. Kim Wan-Joo, a pioneer in ionic 스피드 바카라 사이트 technology in Korea and founder of C-TRI, and CEO Jeong Hotcherl, an expert in pharmacogenomics. Earlier this year, the company completed its leadership team by appointing Dr. Jun Johnson SG, recognized as a leading expert in venture architect and technology management, as Chief Strategy Officer (CSO), signaling a strategic push towards external collaboration and business development (BD).
Bion 스피드 바카라 사이트 plans to finalize the biocompatibility and safety assessment of the ionic 스피드 바카라 사이트s it has developed by the end of this year, with the goal of selecting target drugs for application. “We have secured several ionic 스피드 바카라 사이트 candidates that can be optimized and tailored to specific drugs,” Jeong explained. “We intend to identify promising drug candidates under development in Korea and internationally for formulation development, with a particular focus on peptide drugs or ribonucleic acid (RNA) therapeutics as initial targets.”
According to Jeong, ionic 스피드 바카라 사이트s refer to salts that remain in a ‘스피드 바카라 사이트 state’ at temperatures below 100℃. By carefully selecting specific ‘cations’ and ‘anions,’ it is possible to produce salts that maintain a ‘스피드 바카라 사이트 state’ even at room temperature. Unlike conventional solvents, these substances are characterized by high solubility, thermal stability, and ionic conductivity.
“Ionic 스피드 바카라 사이트s enable the production of highly concentrated drug formulations due to their high solubility, significantly enhancing the absorption and bioavailability of peptide drugs by reducing the viscosity of the gastric mucosa and increasing permeability of the epithelial cell layer,” Jeong emphasized. “This technology allows the development of 스피드 바카라 사이트 formulations that offer rapid drug release and absorption at high concentrations, providing a notable advantage over conventional formulations.”
Bion 스피드 바카라 사이트 is focusing on the development of technologies to transform conventional injectable drugs into oral formulations through its next-generation drug delivery platforms based on ionic 스피드 바카라 사이트s. Among its primary targets are GLP-1 series drugs, a class of peptide therapeutics.
While GLP-1 series peptide drugs have achieved blockbuster status globally, they are predominantly available in injection forms, which present several drawbacks, including limited drug distribution, risk of infection, potential damage to blood vessels and nerve tissues, high production costs, complex administration procedures, and low patient adherence.
Specifically, the oral administration and absorption of peptide drugs require overcoming several biological barriers, including the acidic gastric environment, intestinal digestive enzymes, biles, and the presence of intestinal microorganisms. However, Jeong explained that current approaches, such as intestinal patches, intestinal microneedles, and particle-based formulations, often suffer from low bioavailability, limiting their potential to achieve meaningful clinical efficacy.
In contrast, ionic 스피드 바카라 사이트s remain in a 스피드 바카라 사이트 state at body temperature and can function as reaction catalysts even in small amounts. Notably, they possess the unique advantage of effectively penetrating the gastrointestinal mucus layer and epithelial cell layer, greatly enhancing drug absorption.
“Leveraging Bion 스피드 바카라 사이트’s extensive experience in ionic 스피드 바카라 사이트 discovery and synthesis, peptide drug manufacturing, and drug delivery system (DDS) technologies, we are selecting ionic 스피드 바카라 사이트s with exceptional biocompatibility,” Jeong stated. “Based on this foundation, we are developing a lipid nanoparticle (LNP) carrier loaded with a ‘peptide-ionic 스피드 바카라 사이트 conjugate’.”
“The peptide drug delivery system we are developing demonstrates clear advantages in absorption and bioavailability compared with existing physical approaches, such as intestinal patches, intestinal microneedles, and particle formulations,” Jeong further added. “The ionic 스피드 바카라 사이트-based drug delivery platform is expected to be commercialized and secure a position in the global market, leveraging its technological differentiation in the GLP-1 series diabetes and obesity treatment market.”
Celebrating its second anniversary last month, Bion 스피드 바카라 사이트 has gained significant external recognitions for its technological differentiation. One notable achievement is its selection as a K-BioLab Hub membership company. Shortly after its foundation, Bion 스피드 바카라 사이트 was chosen for the Korea Biotechnology Industry Organization (KoreaBio)'s initial support program in May 2023 and subsequently recognized as a top-performing resident company at the Seoul BioHub in July of the same year. Additionally, it was selected as an incubation company by the Incheon Center for Creative Economy and Innovation in December 2024, followed by its inclusion as a K-BioLab Hub membership company in March of this year.
“In January 2024, we filed a domestic patent application for ‘a novel drug formulation utilizing ionic 스피드 바카라 사이트 or eutectic solvents (a mixture of two or more substances that exhibit a lower melting point together than individually),’ and in January of this year, we submitted a PCT international patent application for the same technology,” Jeong expressed. “We are currently preparing to file a patent for ‘a lipid-based nanoparticle carrier loaded with an ionic 스피드 바카라 사이트-biologic conjugate.’”
Bion 스피드 바카라 사이트 aims to secure the necessary R&D funding by the end of the year through its first seed investment round. In addition, the company plans to achieve both TIPS (Tech Incubator Program for Startups) selection and foreign investment within the year.
“The ionic 스피드 바카라 사이트 technology developed by our company has the potential for broad application across various areas, including peptide drugs, RNA therapeutics, and vaccines,” Jeong said. “We aim to create synergies through strategic partnerships, leveraging our differentiated platform competitiveness.”
“We have recently initiated a project in collaboration with Professor Kim Young-Joo’s team at Ewha Womans University Mokdong Hospital, aimed at using ionic 스피드 바카라 사이트s to administer probiotics to pregnant women at high risk of premature birth and to prevent metabolic diseases,” he further noted.
Finally, Jeong emphasized, “The technology transfer successes of leading Korean biotech platform companies like Alteogen and D&D Pharmatech serve as the model we aspire to follow,” adding, “With our differentiated technology for converting injectable formulations into oral formulations, we aim to establish ourselves as a leading drug delivery platform company.”